Behboudi-Gandevani Samira, Amiri Mina, Bidhendi Yarandi Razieh, Ramezani Tehrani Fahimeh
1Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, No 24, Parvane Street, Yaman Street, Velenjak, Tehran, P.O.Box: 19395-4763, Iran.
2Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Poor sina street, Tehran, P.O.Box: 1417653761, Iran.
Diabetol Metab Syndr. 2019 Feb 1;11:11. doi: 10.1186/s13098-019-0406-1. eCollection 2019.
The absence of universal gold standards for screening of gestational diabetes (GDM) has led to heterogeneity in the identification of GDM, thereby impacting the accurate estimation of the prevalence of GDM. We aimed to evaluate the effect of different diagnostic criteria for GDM on its prevalence among general populations of pregnant women worldwide, and also to investigate the prevalence of GDM based on various geographic regions.
A comprehensive literature search was performed in PubMed, Scopus and Google-scholar databases for retrieving articles in English investigating the prevalence of GDM. All populations were classified to seven groups based-on their diagnostic criteria for GDM. Heterogeneous and non-heterogeneous results were analyzed using the fixed effect and random-effects inverse variance model for calculating the pooled effect. Publication bias was assessed by Begg's test. The Meta-prop method was used for the pooled estimation of the prevalence of GDM. Meta-regression was conducted to explore the association between prevalence of GDM and its diagnostic criteria. Modified Newcastle-Ottawa Quality Assessment Scale for nonrandomized studies was used for quality assessment of the studies included; the ROBINS and the Cochrane Collaboration's risk of bias assessment tools were used to evaluate the risk of bias.
We used data from 51 population-based studies, i.e. a study population of 5,349,476 pregnant women. Worldwide, the pooled overall-prevalence of GDM, regardless of type of screening threshold categories was 4.4%, (95% CI 4.3-4.4%). The pooled overall prevalence of GDM in the diagnostic threshold used in IADPSG criteria was 10.6% (95% CI 10.5-10.6%), which was the highest pooled prevalence of GDM among studies included. Meta-regression showed that the prevalence of GDM among studies that used the IADPSG criteria was significantly higher (6-11 fold) than other subgroups. The highest and lowest prevalence of GDM, regardless of screening criteria were reported in East-Asia and Australia (Pooled-P = 11.4%, 95% CI 11.1-11.7%) and (Pooled-P = 3.6%, 95% CI 3.6-3.7%), respectively.
Over the past quarter century, the diagnosis of gestational diabetes has been changed several times; along with worldwide increasing trend of obesity and diabetes, reducing the threshold of GDM is associated with a significant increase in the incidence of GDM. The harm and benefit of reducing the threshold of diagnostic criteria on pregnancy outcomes, women's psychological aspects, and health costs should be evaluated precisely.
缺乏用于筛查妊娠期糖尿病(GDM)的通用金标准导致了GDM识别的异质性,从而影响了对GDM患病率的准确估计。我们旨在评估不同的GDM诊断标准对全球孕妇总体人群中GDM患病率的影响,并基于不同地理区域调查GDM的患病率。
在PubMed、Scopus和谷歌学术数据库中进行全面的文献检索,以检索用英文研究GDM患病率的文章。根据其GDM诊断标准,所有人群被分为七组。使用固定效应和随机效应逆方差模型分析异质性和非异质性结果,以计算合并效应。通过Begg检验评估发表偏倚。Meta-prop方法用于GDM患病率的合并估计。进行Meta回归以探讨GDM患病率与其诊断标准之间的关联。使用针对非随机研究的改良纽卡斯尔-渥太华质量评估量表对纳入研究进行质量评估;使用ROBINS和Cochrane协作偏倚风险评估工具评估偏倚风险。
我们使用了来自51项基于人群的研究的数据,即5349476名孕妇的研究人群。在全球范围内,无论筛查阈值类别如何,GDM的合并总体患病率为4.4%(95%CI 4.3 - 4.4%)。国际糖尿病与妊娠研究组协会(IADPSG)标准中使用的诊断阈值下GDM的合并总体患病率为10.6%(95%CI 10.5 - 10.6%),这是纳入研究中GDM合并患病率最高的。Meta回归显示,使用IADPSG标准的研究中GDM的患病率显著高于其他亚组(6至11倍)。无论筛查标准如何,GDM患病率最高和最低的分别是东亚和澳大利亚(合并P = 11.4%,95%CI 11.1 - 11.7%)和(合并P = 3.6%,95%CI 3.6 - 3.7%)。
在过去的四分之一个世纪里,妊娠期糖尿病的诊断已经改变了几次;随着全球肥胖和糖尿病的上升趋势,降低GDM阈值与GDM发病率的显著增加相关。应精确评估降低诊断标准阈值对妊娠结局、女性心理方面和健康成本的危害和益处。